PMID- 17307984
OWN - NLM
STAT- MEDLINE
DCOM- 20070706
LR  - 20181113
IS  - 0066-4804 (Print)
IS  - 1098-6596 (Electronic)
IS  - 0066-4804 (Linking)
VI  - 51
IP  - 5
DP  - 2007 May
TI  - Rapid bactericidal activity of daptomycin against methicillin-resistant and 
      methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured 
      with bioluminescent bacteria.
PG  - 1787-94
AB  - The rising rates of antibiotic resistance accentuate the critical need for new 
      antibiotics. Daptomycin is a new antibiotic with a unique mode of action and a 
      rapid in vitro bactericidal effect against gram-positive organisms. This study 
      examined the kinetics of daptomycin's bactericidal action against peritonitis 
      caused by methicillin-susceptible Staphylococcus aureus (MSSA) and 
      methicillin-resistant S. aureus (MRSA) in healthy and neutropenic mice and 
      compared this activity with those of other commonly used antibiotics. CD-1 mice 
      were inoculated intraperitoneally with lethal doses of MSSA (Xen-29) or MRSA 
      (Xen-1), laboratory strains transformed with a plasmid containing the lux operon, 
      which confers bioluminescence. One hour later, the animals were given a single 
      dose of daptomycin at 50 mg/kg of body weight subcutaneously (s.c.), nafcillin at 
      100 mg/kg s.c., vancomycin at 100 mg/kg s.c., linezolid at 100 mg/kg via gavage 
      (orally), or saline (10 ml/kg s.c.). The mice were anesthetized hourly, and 
      photon emissions from living bioluminescent bacteria were imaged and quantified. 
      The luminescence in saline-treated control mice either increased (neutropenic 
      mice) or remained relatively unchanged (healthy mice). In contrast, by 2 to 3 h 
      postdosing, daptomycin effected a 90% reduction of luminescence of MSSA or MRSA 
      in both healthy and neutropenic mice. The activity of daptomycin against both 
      MSSA and MRSA strains was superior to those of nafcillin, vancomycin, and 
      linezolid. Against MSSA peritonitis, daptomycin showed greater and more rapid 
      bactericidal activity than nafcillin or linezolid. Against MRSA peritonitis, 
      daptomycin showed greater and more rapid bactericidal activity than vancomycin or 
      linezolid. The rapid decrease in the luminescent signal in the daptomycin-treated 
      neutropenic mice underscores the potency of this antibiotic against S. aureus in 
      the immune-suppressed host.
FAU - Mortin, Lawrence I
AU  - Mortin LI
AD  - Cubist Pharmaceuticals Inc, Lexington, MA 02421, USA. Lawrence.Mortin@cubist.com
FAU - Li, Tongchuan
AU  - Li T
FAU - Van Praagh, Andrew D G
AU  - Van Praagh AD
FAU - Zhang, Shuxin
AU  - Zhang S
FAU - Zhang, Xi-Xian
AU  - Zhang XX
FAU - Alder, Jeff D
AU  - Alder JD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070216
PL  - United States
TA  - Antimicrob Agents Chemother
JT  - Antimicrobial agents and chemotherapy
JID - 0315061
RN  - 0 (Acetamides)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Oxazolidinones)
RN  - ISQ9I6J12J (Linezolid)
RN  - NWQ5N31VKK (Daptomycin)
SB  - IM
MH  - Acetamides/pharmacology
MH  - Animals
MH  - Anti-Bacterial Agents/*pharmacology
MH  - Colony Count, Microbial
MH  - Daptomycin/*pharmacology/therapeutic use
MH  - Female
MH  - Linezolid
MH  - Luminescent Measurements
MH  - *Methicillin Resistance
MH  - Mice
MH  - Microbial Sensitivity Tests
MH  - Neutropenia/drug therapy
MH  - Oxazolidinones/pharmacology
MH  - Peritonitis/*drug therapy
MH  - Staphylococcus aureus/*drug effects
PMC - PMC1855546
EDAT- 2007/02/20 09:00
MHDA- 2007/07/07 09:00
PMCR- 2007/09/01
CRDT- 2007/02/20 09:00
PHST- 2007/02/20 09:00 [pubmed]
PHST- 2007/07/07 09:00 [medline]
PHST- 2007/02/20 09:00 [entrez]
PHST- 2007/09/01 00:00 [pmc-release]
AID - AAC.00738-06 [pii]
AID - 0738-06 [pii]
AID - 10.1128/AAC.00738-06 [doi]
PST - ppublish
SO  - Antimicrob Agents Chemother. 2007 May;51(5):1787-94. doi: 10.1128/AAC.00738-06. 
      Epub 2007 Feb 16.